For most of working history, menopause was managed at work the way it was managed everywhere: privately, silently and alone. That settlement has broken in the past decade, and what has replaced it is worth setting out plainly, because the subject now sits at the intersection of medicine, employment law and workforce economics.
The scale justifies the attention. Menopause typically arrives between 45 and 55, precisely the years when women hold their most senior roles, and the transition years around it can bring disrupted sleep, hot flushes, anxiety, and the concentration and memory effects known bluntly as brain fog. Surveys of working women report a large majority experiencing symptoms that affect work, sizeable minorities reducing hours or declining promotion because of them, and a persistent single-digit percentage leaving employment altogether. Multiplied across the economy, that is an annual loss of experienced staff no employer would accept from any other single cause.
The medicine has moved faster than the folklore. Hormone replacement therapy, whose reputation was damaged by early-2000s studies that later reanalysis heavily qualified, is now supported by UK guidance as an effective first-line treatment for symptomatic women, with risks that are small for most and a conversation, not a prohibition, for the rest. Non-hormonal options exist for those who cannot or prefer not to take it. The practical barrier has often been access: short GP appointments, patchy specialist provision, and a period of well-publicised supply shortages taught many women to expect a fight that current guidance does not intend.
The workplace half of the problem
Employment law reached the subject through the general route. Menopause is not a standalone protected characteristic, but tribunal rulings have established that severe symptoms can amount to a disability under the Equality Act, triggering the duty of reasonable adjustment, and cases have also proceeded on sex and age discrimination grounds. Employers have noticed the case law, and regulators have published guidance saying the quiet part audibly: dismissing or managing someone out over unadjusted menopause symptoms is a legal risk.
The adjustments themselves are almost embarrassingly cheap, which is the strongest argument that the historical barrier was silence rather than cost. Temperature control or a desk fan, uniform flexibility, later starts after bad nights, flexibility around the timing of demanding meetings, and a named route to ask without a public explanation cover most reported needs. The organisations that do this well pair the policy with permission, training managers so the first conversation is not the employee's burden to engineer.
None of this medicalises ordinary ageing or obliges anyone to discuss their biology at work. It replaces a tax that fell on one group at their professional peak with a set of tools that cost little. The silence was the expensive part.
